Richa Rathore

10PUBLICATIONS
22CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNeurology and neuromuscular diseasesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 11, 2025
PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma.

Toshinao Oyama, Caitlyn B Brashears, Richa Rathore

|Apr 14, 2022
Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102.

Caitlyn B Brashears, Bethany C Prudner, Richa Rathore

|May 24, 2021
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.

Richa Rathore, Brian Van Tine

|Apr 03, 2021
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.

Richa Rathore, Brian A Van Tine

|Mar 26, 2021
Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

Brian A Van Tine, Angela C Hirbe, Peter Oppelt

Pageof 2